The company will not receive any of the proceeds from the sale by the selling stockholders of the shares of common stock.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates
- Windtree Therapeutics reports Q2 EPS ($20.91) vs. ($29.47) last year
- Windtree Therapeutics Board Reshuffles, Appoints New Directors
- Windtree Announces New Additions and Changes to Its Board of Directors
- Windtree Therapeutics Inc trading resumes